Determination of Ganciclovir and its prodrug Valganciclovir by hydrophilic interaction liquid chromatography-tandem mass spectrometry

被引：29

作者：

Heinig, Katja ^{[1
]}

Wirz, Thomas ^{[1
]}

Gajate-Perez, Almudena ^{[1
]}

Belli, Sara ^{[1
]}

机构：

[1] F Hoffmann La Roche & Co Ltd, Pharma Res, Nonclin Safety, Bioanalyt Sect, CH-4070 Basel, Switzerland

来源：

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2011年 / 879卷 / 5-6期

关键词：

Ganciclovir (GCV); Valganciclovir (VGC); Valcyte (R); Plasma; Liquid chromatography-tandem mass spectrometry (LC-MS/MS); Hydrophilic interaction liquid chromatography (HILIC); Dried blood spots (DBS); HUMAN PLASMA; HPLC METHOD; PHARMACOKINETICS; METABOLITE;

D O I：

10.1016/j.jchromb.2010.12.033

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

This manuscript describes the determination of Ganciclovir (GCV), active component of the antiviral drug Valcyte(R), and its ester prodrug Valganciclovir (VGC) in human and rat plasma, using liquid chromatography coupled to tandem mass spectrometry. Protein precipitation with acetonitrile was followed by hydrophilic interaction liquid chromatography on a silica column with 4 min run time. After electrospray ionization, the compounds were detected in positive ion selected reaction monitoring (SRM) mode. The lower limits of quantification (LLOQ) were 16 ng/mL for GCV and 4 ng/mL for VGC in human and rat plasma. Inter-day and intra-day precisions and inaccuracies were below 15% and between 85 and 115%, respectively. Five-fold deuterated GCV and VGC were used as internal standards and compensated for any matrix effect. The method was successfully applied to samples from a rat pharmacokinetic study. The feasibility of blood analysis as dried blood spots (DBS) was investigated. (C) 2011 Elsevier B.V. All rights reserved.

引用

页码：436 / 442

页数：7

共 22 条

[1] Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation [J].

Acosta, E. P. ;

Brundage, R. C. ;

King, J. R. ;

Sanchez, P. J. ;

Sood, S. ;

Agrawal, V. ;

Homans, J. ;

Jacobs, R. F. ;

Lang, D. ;

Romero, J. R. ;

Griffin, J. ;

Cloud, G. ;

Whitley, R. ;

Kimberlin, D. W. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (06) :867-872

[2]

[Anonymous], 2001, FDA Guidance for industry: Bioanalytical method validation

[3]

Boscha ME, 2009, ASIAN J PHARM SCI, V4, P254

[4] Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers [J].

Brown, F ;

Banken, L ;

Saywell, K ;

Arum, I .

CLINICAL PHARMACOKINETICS, 1999, 37 (02) :167-176

[5] Hydrophilic interaction liquid chromatography/electrospray mass spectrometry determination of acyclovir in pregnant rat plasma and tissues [J].

Brown, SD ;

White, CA ;

Bartlett, MG .

RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2002, 16 (19) :1871-1876

[6] Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl [J].

Burri, M ;

Wiltshire, H ;

Kahlert, C ;

Wouters, G ;

Rudin, C .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (03) :263-266

[7] An HPLC method for the determination of diastereomeric prodrug RS-79070-004 in human plasma [J].

Chan, R ;

LaFargue, JA ;

Reeve, RL ;

Tam, Y ;

Tarnowski, T .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, 21 (03) :647-656

[8] A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum [J].

Chu, F ;

Kiang, CH ;

Sung, ML ;

Huang, B ;

Reeve, RL ;

Tarnowski, T .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, 21 (03) :657-667

[9]

*EMA, 2009, EMA DRAFT GUID VAL B

[10]

*ENT AG, 2008, TOXKIN VERS 3 5 3

← 1 2 3 →